Children's Hospital Los Angeles

chla.org

Total trials

147

Active

51

Phase 3

6

Total enrollment

27,098

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 12 of 12 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Ferric derisomaltose1
NovaFerrum1
Dexamethasone1
Randomization of Propofol or Dexmedetomidine1
Feiba1
Fluoxetine1
Semaglutide 2.4 mg1
Maralixibat 9.5 MG/ML [Livmarli]1
Crizanlizumab1
Butyrate1
FMT versus placebo1
Dinutuximab with Chemotherapy1

Next readouts

  • 2022-10
  • 2025-02-23
  • 2026-01
  • 2026-03
  • 2026-04-01
  • 2027-06-30
  • 2027-06-30
  • 2028-07-01
  • 2028-09-01
  • 2028-09-01

Top conditions

  • Pediatric Obesity6
  • Medication Adherence5
  • Pain5
  • Sickle Cell Disease5
  • Anxiety4
  • Type 2 Diabetes4
  • Parenting3
  • Type 1 Diabetes3

Frequently asked questions about Children's Hospital Los Angeles

How many clinical trials does Children's Hospital Los Angeles have on ClinicalTrials.gov?
Children's Hospital Los Angeles is listed as the lead sponsor on 147 clinical trials in ClinicalTrials.gov, 51 of which are currently active (recruiting, enrolling, or ongoing).
How many of Children's Hospital Los Angeles's trials are in Phase 3?
6 of Children's Hospital Los Angeles's trials are in Phase 3, spread across 12 active drug programs.
What therapeutic areas does Children's Hospital Los Angeles focus on?
Children's Hospital Los Angeles's most-studied conditions on ClinicalTrials.gov are Pediatric Obesity, Medication Adherence, Pain, Sickle Cell Disease, Anxiety.
When are Children's Hospital Los Angeles's next clinical trial readouts?
Children's Hospital Los Angeles has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab”, expected around 2022-10.